Clarius Group LLC Sells 459 Shares of Humana Inc. $HUM

Clarius Group LLC trimmed its stake in Humana Inc. (NYSE:HUM) by 31.1% in the second quarter, HoldingsChannel reports. The firm owned 1,017 shares of the insurance provider’s stock after selling 459 shares during the period. Clarius Group LLC’s holdings in Humana were worth $249,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Willner & Heller LLC grew its holdings in Humana by 23.5% in the second quarter. Willner & Heller LLC now owns 2,180 shares of the insurance provider’s stock worth $533,000 after purchasing an additional 415 shares during the period. AMF Tjanstepension AB acquired a new stake in Humana in the second quarter worth $18,073,000. Segment Wealth Management LLC acquired a new stake in Humana in the second quarter worth $221,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Humana by 9.2% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,992 shares of the insurance provider’s stock worth $4,154,000 after purchasing an additional 1,432 shares during the period. Finally, Tower View Wealth Management LLC acquired a new stake in Humana in the second quarter worth $88,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Evercore ISI initiated coverage on shares of Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 price objective for the company. Sanford C. Bernstein lifted their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Guggenheim reiterated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Finally, Royal Bank Of Canada lifted their price objective on shares of Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a report on Thursday, August 21st. Seven research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $293.50.

Humana Stock Up 0.0%

Humana stock opened at $295.26 on Wednesday. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The stock has a market cap of $35.51 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 1.73 and a beta of 0.42. The firm’s 50-day simple moving average is $277.31 and its 200 day simple moving average is $257.76. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. During the same quarter last year, the firm posted $6.96 earnings per share. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. Research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana’s payout ratio is 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.